摘要
Abstract
Objective To observe the clinical effect of simvastatin on interleukin-6 and matrix metalloproteinase-2 in cerebrospinal fluid patients with subarachnoid hemorrhage (SAH).Methods A total of 40 SAH patients were randomly divided into treatment group and control group,each group 20 cases.Control group was received lumbar drainage treatment.Treatment group was orally given simvastatin 20 mg on the basis of control group.All patients were treated for 10 d.The interleukin 6,matrix metalloproteinase-2 in cerebrospinal fluid in two group were observed in 1,3,5,7,10 d after treatment.Results The levels of interleukin-6 in cerebrospinal fluid after 5,7,10 d treatment in treatment group were (186.25 ±17.43),(147.31 ±18.72),(100.19 ±11.54)mg · mL-1,had significant difference with those in control group,which were (215.19 ±21.01),(185.09 ± 17.41),(150.25 ± 17.20) mg · mL-1 (P ＜ 0.01).The levels of matrix metalloproteinase-2 in cerebrospinal fluid after 3,5,7,10 d treatment in treatment group were (100.34 ± 21.51),(131.22 ± 19.75),(103.22 ± 14.51),(80.23 ± 15.41)mg · mL-1,had significant difference with those in control group,which were (121.33 ± 23.13),(169.42 ±25.27),(158.51 ± 18.52),(102.22 ± 23.11) mg · mL-1 (P ＜ 0.01).There was 1 case of creatine kinase increased in treatment group,and no adverse drug reaction occurred in control group.Conclusion Simvastatin in patients with SAH can reduce the levels of cerebrospinal fluid interleukin-6,matrix metalloproteinase-2.关键词
辛伐他汀/蛛网膜下腔出血/腰大池引流/白细胞介素-6/基质金属蛋白酶-2Key words
simvastatin/subarachnoid hemorrhage/lumbar subarachnoid drainage/interleukin-6/matrix metalloproteinase-2分类
医药卫生
